Professor Khosrotehrani is a clinical scientist, dermatologist, interested in skin biology, regenerative medicine and skin cancer. He leads the Experimental Dermatology Group at the University of Queensland Diamantina Institute within the Translational Research Institute in Brisbane, Australia. He is also the deputy director of the Australian Skin and Skin Cancer Research Centre in Brisbane. Dr Khosrotehrani obtained his MD from the Cochin-Port Royal School of Medicine at René Descartes University, Paris, France, where he specialized in Dermatology. He is a former graduate of the Ecole Normale Supérieure and the Institut Pasteur of Paris (Université Paris VI, Pierre et Marie Curie) where he obtained a PhD in Physiology and Physiopathology. He is a fellow of the Australian College of Dermatologists and a practising dermatologist at the Princess Alexandra Hospital, Prince Charles Hospital and the Skin and Cancer Foundation’s Queensland Institute of Dermatology.
During his post-doctoral training at Tufts-New England Medical Center, Boston, USA, Dr. Khosrotehrani helped establish the contribution of fetal stem cells to tissue repair by demonstrating their multipotent capacity with a specific potency towards the endothelial lineage. The originality of this work was acknowledged by the NHMRC through an achievement award (2011) and an NHMRC excellence award (2016). He is currently a fellow of the NHMRC of Australia. The main focus of his laboratory is on regenerative medicine and stem cell biology in particular in injury response in skin wounds and skin cancer and how these responses contribute to cancer initiation and progression. Translating his laboratory findings, Dr Khosrotehrani is leading innovative clinical trials in wound healing, keratinocyte cancers and melanoma.
Professor Soyer is an academic dermatologist with over 30 years experience in the field. He was appointed as the inaugural Chair in Dermatology by The University of Queensland (UQ) in 2007 and was Director of the Princess Alexandra Hospital (PAH) Dermatology Department from 2008-2023. His clinical background drives a strong focus on translational skin cancer research.
Professor Soyer is internationally recognised in the field of dermatology with particular expertise in the areas of preventative dermatooncology, dermatopathology and dermatologic imaging (dermoscopy and reflectance confocal microscopy). Within the dermatology discipline he is a pioneer and world leader in the field of dermoscopy of pigmented skin lesions, a non-invasive diagnostic method. He has led the development of the morphologic classification system currently used worldwide.
His main research focus is skin cancer (both melanoma and keratinocyte skin cancer), with a particular interest in technological innovations and their ability to impact early detection strategies and expand the concept and applications of teledermatology and teledermoscopy. A $9.9M infrastructure grant awarded in 2018 by the Australian Cancer Research Foundation (ACRF) has enabled establishment of the collaborative Australian Centre of Excellence in Melanoma Imaging and Diagnosis (ACEMID); installing 15 3D total body imaging systems, linked by a research network, across Australia’s east cost to facilitate research in the early detection of melanoma. ACRF ACEMID is currently conducting Australia’s largest melanoma cohort study targeting 15,000 participants, with the multi-modal research data being collected and stored in a national research repository. This unprecedented data resource will allow many unanswered research questions in the field to be addressed and will facilitate advancements in artificial intelligence, resulting in the development of reliable, evidence-based solutions to transform melanoma early detection.
Professor Soyer has an extensive publication record with over 680 publications to date, with more than 700 citations per year (in the last 5 years) and an h-index of 96 (Google Scholar). His textbook entitled "Dermoscopy - The Essentials 3rd Edition", co-authored with G Argenziano, R Hofmann-Wellenhof and I Zalaudek is considered a world-leading textbook in the field.
Professor Soyer has been awarded two competitive fellowships while at UQ: a Medical Research Future Fund (MRFF) Next Generation Clinical Researchers Program Practitioner Fellowship (2018-2022) and an NHMRC Practitioner Fellowship (2012-2016). The NHMRC Practitioner Fellowship was acknowledged in the NHMRC ‘10 of the Best NHMRC research projects 2016’ publication. He has also been awarded 1 NHMRC European Union Collaborative Research Grant (CIA), 1 NHMRC Synergy Grant (CIC), 1 NHMRC Clinical Trials and Cohort Studies Grant (CIC), 1 MRFF Targeted Health System and Community Organisation Research Grant (CIC), 3 NHMRC Centre of Research Excellence Grants (CIA, CIB, CIE), 4 NHMRC Project Grants (CIA, CIA, CIB, CID), 2 NHMRC Partnership Grants (CIA, CIB), 2 ARC Discovery Project Grants (CIB, CID), and a Queensland Genomic Health Alliance (QGHA) Demonstration Project Grant (CIA), with many additional projects funded through other competitive, industry and philanthropic funding sources. In total, through his involvement as an investigator, he has achieved over $43M in research funding for UQ since 2014.
Professor Rachel Thomson is a Head of the Greenslopes Clinical Unit, Thoracic Physician and clinical researcher working at Greenslopes Private Hospital.
She has an international reputation in the area of Pulmonary Nontuberculous mycobacterial disease. She has published widely in the area and is regularly invited to speak at international and national meetings.https://medical-school.uq.edu.au/research/ntm-research-group
Her current research focuses on immunological and environmental aspects of susceptibility to NTM infection, characteristics of the lung and gut microbiome in NTM, and improving treatment outcomes.
In a clinical capacity, Professor Thomson is able to offer patients expert management of their disease at Pulmedica, Greenslopes Private Hospital, at public clinics at The Prince Charles Hospital and the MetroSouth Clinical TB service of the Princess Alexandra Hospital and via telehealth for patients across Australia. Patients can also access novel treatments through clinical trials in both the private and public sector.
Prof Thomson also has a special interest in respiratory problems of the elite athlete. This includes asthma management, vocal cord dysfunction, and the requirements of national and international doping organisations for asthma medications.
Zephanie is a Senior Research Fellow and occupational therapist based at the Child Health Research Centre, and a member of the management team of the Centre for Children’s Burns and Trauma Research, Brisbane. She has a clinical background specialising in paediatrics and burn care. She has worked clinically and in management positions at Royal Children’s Hospital, Brisbane, in private practice and in research capacity building positions in hospitals and health services.
Since 2013 Zephanie’s research has focussed on developing and validating patient-reported outcome measures, as well as using these measures therapeutically for clinical decision making. She led the development of four versions of the Brisbane Burn Scar Impact Profile which have been translated into Czech and are undergoing cross-cultural validation for Brazilian Portuguese. She has a vision of providing all children and their caregivers with an opportunity to communicate their needs and priorities during treatment in a paediatric hospital or health service.
Her current program of work includes collaborative work with children, their caregivers and health professionals to co-design and test the effectiveness and implementation of technology-based interventions in clinical settings to improve quality of life. These interventions include a web-based intervention for paediatric health professionals to support the psychosocial health of families with a child who has experienced physical trauma, and an electronic intervention for children with skin conditions and their caregivers that provides feedback about the patient's health-related quality of life to health professionals. Zephanie also has a continued interest in investigating the effectiveness and implementation of novel interventions to prevent or improve the impact of skin conditions in children and their families. This includes the use of ablative fractional CO2 laser, medical needling, pressure garment and silicone therapy, medical hypnosis and interventions to promote adherence and reduce the burden of treatment.
Dr Lena von Schuckmann is a clinician researcher, with dual medical specialist training in dermatology and general practice. Her research is focused on skin cancer prevention, early detection, and optimising skin cancer treatment. She is passionate about improving the cancer journey for patients.
She works as a consultant dermatologist at the Princess Alexandra Hospital, Sunshine Coast University Hospital and private clinics in Spring Hill and the Samford Valley.
